- Home
- IIIN vs ABUS Comparison
IIIN vs ABUS Comparison
Compare IIIN & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IIIN
- ABUS
- Stock Information
- Founded
- IIIN 1953
- ABUS 2005
- Country
- IIIN United States
- ABUS United States
- Employees
- IIIN N/A
- ABUS N/A
- Industry
- IIIN Steel/Iron Ore
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- IIIN Industrials
- ABUS Health Care
- Exchange
- IIIN Nasdaq
- ABUS Nasdaq
- Market Cap
- IIIN 704.8M
- ABUS 685.7M
- IPO Year
- IIIN N/A
- ABUS N/A
- Fundamental
- Price
- IIIN $38.44
- ABUS $3.18
- Analyst Decision
- IIIN
- ABUS Strong Buy
- Analyst Count
- IIIN 0
- ABUS 4
- Target Price
- IIIN N/A
- ABUS $5.50
- AVG Volume (30 Days)
- IIIN 124.9K
- ABUS 805.4K
- Earning Date
- IIIN 07-17-2025
- ABUS 07-31-2025
- Dividend Yield
- IIIN 2.87%
- ABUS N/A
- EPS Growth
- IIIN N/A
- ABUS N/A
- EPS
- IIIN 1.16
- ABUS N/A
- Revenue
- IIIN $570,455,000.00
- ABUS $6,403,000.00
- Revenue This Year
- IIIN $22.06
- ABUS $3.35
- Revenue Next Year
- IIIN $6.70
- ABUS N/A
- P/E Ratio
- IIIN $33.78
- ABUS N/A
- Revenue Growth
- IIIN N/A
- ABUS N/A
- 52 Week Low
- IIIN $22.49
- ABUS $2.71
- 52 Week High
- IIIN $39.26
- ABUS $4.73
- Technical
- Relative Strength Index (RSI)
- IIIN 64.28
- ABUS 42.03
- Support Level
- IIIN $38.38
- ABUS $3.04
- Resistance Level
- IIIN $39.26
- ABUS $3.65
- Average True Range (ATR)
- IIIN 0.91
- ABUS 0.14
- MACD
- IIIN 0.22
- ABUS -0.03
- Stochastic Oscillator
- IIIN 83.09
- ABUS 26.42
About IIIN Insteel Industries Inc.
Insteel Industries Inc manufactures steel wire reinforcing products for concrete construction applications. It manufactures and markets PC strand and welded wire reinforcement, including ESM, concrete pipe reinforcement, and standard welded wire reinforcement. The company's products are sold to manufacturers of concrete products that are used in nonresidential construction. Its concrete reinforcing products consist of two product lines: PC strand and WWR. Insteel generates its geographical revenue from the United States.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.